Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17253049 | 0.77 | L3MBTL1 (0.42) | CYP2C19MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16289613 | 0.76 | UHRF1 (0.45) | DYRK1AMEN1KMT2ASMN1; SMN2NOS3 | |
| SCHEMBL23717247 | 0.76 | TRPV4 (0.32) | CYP1A2CYP2D6CYP2C19NOS3NOS2 | |
| SCHEMBL23005292 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP2C19NOS3NOS2 | |
| SCHEMBL30488651 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP2C19NOS3NOS2 | |
| SCHEMBL2303631 | 0.76 | NOS3 (0.38) | CYP1A2NPC1RAB9AABL1MEN1 | |
| SCHEMBL16289610 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP2C19NOS3NOS2 | |
| SCHEMBL2304236 | 0.74 | KDM4C (0.50) | KMOAURKATPX2SYK | |
| SCHEMBL19023296 | 0.73 | DEGS1 (0.36) | TLR7CYP1A2CYP2C19KMT2A | |
| SCHEMBL9005090 | 0.73 | CYP11B1 (0.43) | TRPV1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| CN-119161343-A | Bridged pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119143780-A | Lp-PLA2 inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119080800-A | Tricyclic pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-114057740-B | Spiropyrimidinone derivatives, method for the production thereof, pharmaceutical compositions and use thereof | 上海赛默罗生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4324835-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-02-21 | — | — | EP | disclosed |
| CN-114805389-B | Tricyclic dihydro-imidazo pyrimidinone derivatives, preparation method, pharmaceutical compositions and uses thereof | 上海赛默罗生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109471-A1 | SPIRO PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-115925721-A | Pyrimidone tricyclic derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022233302-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | 上海赛默罗生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| CN-115304620-A | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| EP-4056571-A1 | TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
| CN-114805389-A | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-112778331-B | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | PLA2G1B, LYPLAL1, PLA2G12B | TRPV1 1557/4885TLR7 1152/4885KMO 1192/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | TRPV1 90/4885TLR7 201/4885KMO 3918/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | TRPV1 185/4885TLR7 512/4885KMO 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.